Compare Amphastar Pharmaceuticals Inc (AMPH) vs ServiceNow Inc (NOW) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

ServiceNow (NOW) trades at $107.71, down 1.04% today, with a bullish technical outlook from moving averages and strong fundamental growth. Revenue grew from $7.2B in 2022 to $13.3B in 2025, with net income reaching $1.75B. The stock shows robust cash flow generation and high profitability margins, though valuation multiples remain elevated. Recent news highlights AI-driven growth opportunities and conference presentations reinforcing business momentum.

Outlook remains positive with 85.5% analyst buy ratings and a $138.39 consensus target, implying 28% upside. Key risks include high P/E of 64.11, competitive pressures in enterprise software, and execution challenges in scaling AI offerings. Earnings consistency and margin sustainability are critical for maintaining premium valuation amid market volatility.